CN114832012B - Ce-MOF nano material with oxidation resistance, preparation method and application - Google Patents
Ce-MOF nano material with oxidation resistance, preparation method and application Download PDFInfo
- Publication number
- CN114832012B CN114832012B CN202210292346.8A CN202210292346A CN114832012B CN 114832012 B CN114832012 B CN 114832012B CN 202210292346 A CN202210292346 A CN 202210292346A CN 114832012 B CN114832012 B CN 114832012B
- Authority
- CN
- China
- Prior art keywords
- mof
- oxidation resistance
- nano material
- preparation
- product
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002086 nanomaterial Substances 0.000 title claims abstract description 41
- 230000003647 oxidation Effects 0.000 title claims abstract description 16
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims abstract description 10
- 206010013774 Dry eye Diseases 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims abstract description 9
- 238000001816 cooling Methods 0.000 claims abstract description 6
- 238000007789 sealing Methods 0.000 claims abstract description 6
- 238000005406 washing Methods 0.000 claims abstract description 6
- 238000000034 method Methods 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 4
- 229910000667 (NH4)2Ce(NO3)6 Inorganic materials 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- -1 polytetrafluoroethylene Polymers 0.000 claims 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims 1
- 239000004810 polytetrafluoroethylene Substances 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 abstract description 18
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 abstract description 15
- 239000002245 particle Substances 0.000 abstract description 10
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 abstract description 6
- 239000002994 raw material Substances 0.000 abstract description 5
- 230000001276 controlling effect Effects 0.000 abstract description 3
- 230000001105 regulatory effect Effects 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 3
- 239000007810 chemical reaction solvent Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000012046 mixed solvent Substances 0.000 abstract description 2
- 239000012621 metal-organic framework Substances 0.000 description 40
- 239000000047 product Substances 0.000 description 15
- 238000011156 evaluation Methods 0.000 description 8
- 208000005494 xerophthalmia Diseases 0.000 description 6
- 230000007423 decrease Effects 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 229910002651 NO3 Inorganic materials 0.000 description 3
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000036542 oxidative stress Effects 0.000 description 3
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 229910052684 Cerium Inorganic materials 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 206010052143 Ocular discomfort Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Abstract
The invention belongs to the field of novel nano biological medicines, and particularly relates to a Ce-MOF nano material with oxidation resistance, a preparation method and application thereof. The preparation method of the Ce-MOF nanomaterial comprises the following steps: the method comprises the steps of taking ceric ammonium nitrate and terephthalic acid as raw materials, taking a mixed solvent system of N, N-dimethylformamide and water as a reaction solvent to obtain a reaction system, reacting the reaction system at 80-120 ℃ under a sealing condition for 0.5-1.5-h, cooling to room temperature, and centrifugally washing to obtain the Ce-MOF nano material. The Ce-MOF nano material prepared by the method provided by the invention has remarkable oxidation resistance, the size of the obtained product can be regulated and controlled by controlling the concentration of the raw materials, the oxidation resistance of the product is gradually enhanced along with the reduction of the particle size of the product, and the obtained Ce-MOF nano material can relieve dry eye symptoms to a certain extent.
Description
Technical Field
The invention belongs to the field of novel nano biological medicines, and particularly relates to a Ce-MOF nano material with oxidation resistance, a preparation method and application thereof.
Background
Dry Eye (DED) is a type of Disease that causes symptoms of ocular discomfort and visual dysfunction due to tear film instability and/or ocular surface damage caused by abnormalities in the amount or mass or fluid dynamics of tear fluid. Dry eye is a clinically common chronic disease of the ocular surface, which is manifested by dry eye feel, foreign body feel, burning feel, itching eyes, blurred vision, vision fluctuation and the like, serious dry eye can cause corneal epithelial defect, vision decline and the like, the morbidity of China is about 21-30%, and the value is still rising. DEDs have varying degrees of impact on the patient's visual function, ability to live in daily life, and professional work. Many in vivo and in vitro studies demonstrate that oxidative stress is indistinguishable from dry eye. Oxidative stress can cause damage to ocular surfaces such as cornea and conjunctiva, which plays an important role in the onset of dry eye. DED animal model studies have shown that oxidative stress damage can be significantly reduced by reducing ROS levels and inhibiting inflammatory cytokines. Thus, scavenging ROS with broad-spectrum antioxidants may be an effective regimen for treating this class of DED, namely, mitigating DED by reducing ROS levels in corneal and conjunctival epithelial cells.
Disclosure of Invention
The invention aims to overcome the defects and the shortcomings of the prior art and provide a Ce-MOF nano material with oxidation resistance, a preparation method and application.
The technical scheme adopted by the invention is as follows: a preparation method of a Ce-MOF nano material with oxidation resistance comprises the following steps: the method comprises the steps of taking ceric ammonium nitrate and terephthalic acid as raw materials, taking a mixed solvent system of N, N-dimethylformamide and water as a reaction solvent to obtain a reaction system, reacting the reaction system at 80-120 ℃ under a sealing condition for 0.5-1.5-h, cooling to room temperature, and centrifugally washing to obtain the Ce-MOF nano material.
The terephthalic acid is dissolved in N, N-dimethylformamide, the ammonium ceric nitrate is dissolved in water, and the ammonium ceric nitrate and the water are uniformly mixed after the ammonium ceric nitrate and the water are fully dissolved to obtain a reaction system.
The volume ratio of the N, N-dimethylformamide to the water is 1:1.
The molar concentration ratio of the terephthalic acid to the ceric ammonium nitrate is 1:1-1.2.
The concentration of terephthalic acid is 10-100mM. The particle size of the product prepared in the concentration range is nano-scale, and the product has oxidation resistance, and the particle size of the product can be reduced along with the reduction of the concentration of the raw materials, so that the regulation and control of the size of the obtained product can be easily realized.
The concentration of terephthalic acid is 10-30mM. The product prepared in the concentration range is an ultra-small Ce-MOF nano material, and can relieve dry eye symptoms.
The Ce-MOF nanomaterial prepared by the preparation method of the Ce-MOF nanomaterial with oxidation resistance.
The application of the Ce-MOF nanomaterial in preparing a medicine for relieving xerophthalmia.
The beneficial effects of the invention are as follows: the Ce-MOF nano material prepared by the method provided by the invention has remarkable oxidation resistance, and the size of the obtained product can be regulated and controlled by controlling the concentration of the raw materials, and the oxidation resistance of the product is gradually enhanced along with the reduction of the particle size of the product. The application result for relieving the xerophthalmia shows that the obtained Ce-MOF nanomaterial can relieve the xerophthalmia to a certain extent. This has important research significance for expanding the application of cerium-based metal-organic framework nanomaterials in the field of ophthalmology.
Drawings
In order to more clearly illustrate the embodiments of the invention or the technical solutions of the prior art, the drawings which are required in the description of the embodiments or the prior art will be briefly described, it being obvious that the drawings in the description below are only some embodiments of the invention, and that it is within the scope of the invention to one skilled in the art to obtain other drawings from these drawings without inventive faculty.
FIG. 1 is an XRD pattern of three Ce-MOF nanomaterials prepared according to the present invention;
FIG. 2 is a SEM photograph of three Ce-MOF nanomaterials and a TEM photograph of an ultra-small Ce-MOF prepared according to the example of the present invention, wherein (a) is a SEM photograph of Ce-MOF1, (b) is a SEM photograph of Ce-MOF2, (c) is a SEM photograph of Ce-MOF3, and (d) is a TEM photograph of Ce-MOF 3;
FIG. 3 shows the removal of three Ce-MOF nanomaterials prepared according to the example of the present inventionH 2 O 2 Evaluation of the ability.
FIG. 4 shows the removal of O from three Ce-MOF nanomaterials prepared in accordance with an example of the present invention 2 - Evaluation of Capacity
FIG. 5 is an evaluation of intracellular oxidation resistance of three Ce-MOF nanomaterials prepared in the example of the present invention;
FIG. 6 is an evaluation of the alleviation of dry eye of ultra-small Ce-MOF nanomaterial (Ce-MOF 3) prepared in the examples of the present invention.
Detailed Description
The present invention will be described in further detail with reference to the accompanying drawings, for the purpose of making the objects, technical solutions and advantages of the present invention more apparent.
Example 1:
will be 0.708 g H 2 BDC (final concentration 80.98 mM) was dissolved in 24 mL DMF, 2.32 g (NH) 4 ) 2 Ce(NO 3 ) 6 (final concentration is 88.16 mM) is dissolved in 24 mL water, and after the two are fully dissolved, the two are mixed and stirred for 10 min. And finally transferring the obtained mixture into a 50 ml polytetrafluoroethylene-lined reaction kettle, sealing, reacting at 100 ℃ for 1 h, naturally cooling to room temperature, and centrifugally washing to obtain the product one (Ce-MOF 1).
Example 2:
will be 0.304 g H 2 BDC (final concentration 40.49 mM) was dissolved in 24 mL DMF, 1.16g (NH) 4 ) 2 Ce(NO 3 ) 6 (final concentration 44.08 mM) was dissolved in 24 mL water, and after both were sufficiently dissolved, they were mixed and stirred for another 10 minutes. And finally transferring the obtained mixture into a 50 ml polytetrafluoroethylene-lined reaction kettle, sealing, reacting at 100 ℃ for 1 h, naturally cooling to room temperature, and centrifugally washing to obtain the product one (Ce-MOF 2).
Example 3:
will be 0.152. 0.152g H 2 BDC (final concentration 20.25 mM) was dissolved in 24 mL DMF, 0.58g (NH) 4 ) 2 Ce(NO 3 ) 6 (final concentration of 22.04 mM) was dissolved in 24 mL water, and after both were sufficiently dissolved, they were mixed and stirred for another 10 minutes. Finally, the mixture is obtainedTransferring into a 50 ml polytetrafluoroethylene-lined reaction kettle, sealing, reacting at 100 ℃ for 1 h, naturally cooling to room temperature, and centrifugally washing to obtain the product one (Ce-MOF 3).
The following are the results of research analysis on the relevant properties of the products obtained in examples 1-3.
From the XRD patterns of three Ce-MOF nanomaterials obtained by regulating and controlling the concentrations of different reactants in FIG. 1, it can be seen that the phase structures of the three obtained Ce-MOF nanomaterials are consistent, and the different concentrations of the reactants have little influence on the phase structure of the product.
From SEM photographs of three Ce-MOF nanomaterials and TEM photographs of ultra-small size Ce-MOF nanomaterials prepared by adjusting the concentrations of different reactants in fig. 2, it can be seen that the particle size of the product sequentially decreases as the concentration of the reactants decreases, from initial 500-1000 nm (Ce-MOF 1), to 50 nm (Ce-MOF 2) of the intermediate product, and final 3-5 nm ultra-small nanoparticles (SEM and TEM) (Ce-MOF 3). It can be seen that the particle size of the product can be well controlled by simply adjusting the concentration of the reactants.
Scavenging H from three Ce-MOF nanomaterials of FIG. 3 2 O 2 The capability evaluation can show that the synthesized three Ce-MOF nano materials with different sizes have the function of removing H 2 O 2 And the scavenging ability gradually increases as the particle size of the material decreases.
Scavenging O from three Ce-MOF nanomaterials of FIG. 4 2 - The capability evaluation can show that the synthesized three Ce-MOF nano materials with different sizes all have the function of removing O 2 - And as the particle size of the material decreases, the scavenging ability gradually increases, and the effectiveness of Ce-MOF2 and Ce-MOF3 are similar.
Evaluation of in vitro intracellular oxidation resistance from three Ce-MOF nanomaterials of fig. 5; compared with the positive control N-acetyl-L-cysteine (NAC) which is commonly used at present, the synthesized Ce-MOF nano materials with three different particle sizes have certain antioxidation effect, and the antioxidation capability is enhanced along with the reduction of the particle size of the materials, so that the materials are obviously less green in visual field.
The evaluation result of the ultra-small Ce-MOF nanomaterial (Ce-MOF 3) in relieving animal xerophthalmia in fig. 6 shows that the animal xerophthalmia with the ultra-small Ce-MOF nanomaterial added dropwise has a lower score than that of the PBS group, which indicates that xerophthalmia is relieved.
The foregoing disclosure is illustrative of the present invention and is not to be construed as limiting the scope of the invention, which is defined by the appended claims.
Claims (3)
1. The preparation method of the Ce-MOF nanomaterial with oxidation resistance is characterized by comprising the following steps of: will be 0.152. 0.152g H 2 BDC was dissolved in 24 mL DMF, 0.58g (NH 4) 2 Ce(NO3) 6 Dissolving in 24 mL water, mixing the two materials after the two materials are fully dissolved, continuously stirring for 10 min, finally transferring the obtained mixture into a 50 ml polytetrafluoroethylene lining reaction kettle, sealing, reacting at 100 ℃ for 1 h, naturally cooling to room temperature, and centrifugally washing to obtain the Ce-MOF nanomaterial.
2. The Ce-MOF nanomaterial prepared by the method for preparing a Ce-MOF nanomaterial with oxidation resistance according to claim 1.
3. Use of a Ce-MOF nanomaterial according to claim 2 for the preparation of a medicament for alleviating dry eye.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210292346.8A CN114832012B (en) | 2022-03-23 | 2022-03-23 | Ce-MOF nano material with oxidation resistance, preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210292346.8A CN114832012B (en) | 2022-03-23 | 2022-03-23 | Ce-MOF nano material with oxidation resistance, preparation method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114832012A CN114832012A (en) | 2022-08-02 |
| CN114832012B true CN114832012B (en) | 2023-10-31 |
Family
ID=82561758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210292346.8A Active CN114832012B (en) | 2022-03-23 | 2022-03-23 | Ce-MOF nano material with oxidation resistance, preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114832012B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109012722A (en) * | 2018-06-12 | 2018-12-18 | 广东工业大学 | It is a kind of using Ce-MOF as the ceria of presoma/titanium nitride nano pipe and its preparation method and application |
| CN110585169A (en) * | 2019-09-12 | 2019-12-20 | 郑州大学 | Preparation method of glucose oxidase modified metal organic framework pharmaceutical composition |
| CN110787584A (en) * | 2019-11-11 | 2020-02-14 | 中国科学院宁波材料技术与工程研究所 | Application of cerium-based metal organic framework structure material in CO2Adsorption separation application of |
| CN113441114A (en) * | 2021-08-04 | 2021-09-28 | 辽宁大学 | Mixed metal MOF and preparation method and application thereof |
-
2022
- 2022-03-23 CN CN202210292346.8A patent/CN114832012B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109012722A (en) * | 2018-06-12 | 2018-12-18 | 广东工业大学 | It is a kind of using Ce-MOF as the ceria of presoma/titanium nitride nano pipe and its preparation method and application |
| CN110585169A (en) * | 2019-09-12 | 2019-12-20 | 郑州大学 | Preparation method of glucose oxidase modified metal organic framework pharmaceutical composition |
| CN110787584A (en) * | 2019-11-11 | 2020-02-14 | 中国科学院宁波材料技术与工程研究所 | Application of cerium-based metal organic framework structure material in CO2Adsorption separation application of |
| CN113441114A (en) * | 2021-08-04 | 2021-09-28 | 辽宁大学 | Mixed metal MOF and preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| A cerium oxide loaded glycol chitosan nano-system for the treatment of dry eye disease;Fan Yu等;《Journal of Controlled Release》(第315期);第40-54页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114832012A (en) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4195084A (en) | Taste-stable aqueous pharmaceutical suspension of tall oil sitosterols and a method for the preparation thereof | |
| US20120244195A1 (en) | Adsorbent for an oral administration, and agent for treating or preventing renal or liver disease | |
| JP2005514433A (en) | Use of inorganic nanoparticles to modify viscosity and other physical properties of ophthalmic / ear pharmaceutical compositions | |
| TW201440790A (en) | Ophthalmic composition, method for preparing the same, and use of the same | |
| WO2008087135A1 (en) | Iron-hydrocarbon complex compounds | |
| DE202013104575U1 (en) | Mixture of microencapsulated amino acids | |
| DE60028152T2 (en) | Solid, stable and concentrated biologically digestible complex of orthosilicic acid and process for its preparation | |
| WO2021168931A1 (en) | Submicro emulsion containing acer truncatum seed oil and preparation method therefor | |
| DE60310605T2 (en) | NANOTE PARTICLES FOR THE ADMINISTRATION OF ACTIVE SUBSTANCES, METHOD FOR THE PRODUCTION OF THESE PARTICLES, AND COMPOSITIONS COMPRISING THEM | |
| CN114832012B (en) | Ce-MOF nano material with oxidation resistance, preparation method and application | |
| CN106511269A (en) | Curcumin nano suspension ophthalmic preparation and preparing method | |
| JP2018525370A5 (en) | Drug-mounted nano-resin particles | |
| WO2017016873A1 (en) | Ophthalmic formulations comprising cooperative complexes of low- and high-molecular-weight hyaluronic acid | |
| JP2001500860A (en) | Pharmaceutical composition having antimicrobial activity | |
| DE60008151T2 (en) | 5-HT2 AGONISTS AS A MEANS FOR CONTROLLING THE EYE PRESSURE AND FOR TREATING GLAUCOMA | |
| JP2001501194A (en) | Gel-forming pharmaceutical composition | |
| Gu et al. | Construction and evaluation of hyaluronic acid–coated flurbiprofen-layered double hydroxide ocular drug delivery system | |
| WO2007003435A2 (en) | Use of activators of the soluble guanylate cyclase for promoting the healing of wounds | |
| CN111870702B (en) | Preparation method and application of nano eye medicine | |
| CN106858610B (en) | The preparation method of a kind of amino acid chelated calcium and including the chelated calcium calcium-supplementing preparation | |
| CN111096950B (en) | Curcumin double-layer emulsion with colon-targeted delivery function and preparation method and application thereof | |
| CN109414407B (en) | Montmorillonite suspension and preparation method thereof | |
| CN107568731B (en) | Coenzyme Q10 fish oil nano emulsion and preparation method and application thereof | |
| EP0641563A1 (en) | Remedy for cataract and production thereof | |
| CN107184545A (en) | A kind of konjaku glucomannan gel for eye and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |